News & Investors

Capital increase 2018

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Capital increase 2018

Below you find further information about the capital increase that was resolved by the Management Board of Epigenomics AG with approval of the Supervisory Board on October 7, 2018.

NOTE:
The information contained on this web page is neither an offer for sale of securities nor solicitation to buy any securities. This information is not for circulation in the United States of America (”United States”) or within the United States (including its territories and dependencies, states and the District of Columbia) and may not be forwarded or circulated to “U.S. persons” (as defined in Regulation S under the U.S. Securities Act of 1933 in its currently applicable form [“Securities Act”]) or to publications with a general circulation in the United States. The information contained on this web page is neither an offer nor a solicitation to buy any securities in the United States. The securities of Epigenomics AG have not been and will not be registered under the provisions of the Securities Act and may not be offered or sold within the United States or to U.S. persons without being registered or without the presentation of an exemption from the registration requirements. There will be no public offering of securities in the United States, the United Kingdom, Australia, Canada, Japan or South Africa.

 

Notification pursuant to Section 8 para. 1 sentence 6 of the German Securities Prospectus Act (Wertpapierprospektgesetz) / October 23, 2018 PDF
Result of capital increase – Publication of Inside Information according to Article 17 MAR / October 23, 2018 PDF
Notification pursuant to Section 8 para. 1 sentence 6 of the German Securities Prospectus Act (Wertpapierprospektgesetz) / October 16, 2018 PDF
Subscription price – Publication of Inside Information according to Article 17 MAR / October 16, 2018 PDF
Prospectus / October 8, 2018 PDF
Subscription offer (Please note: Currently there is only a German version available) / October 8, 2018 PDF
Press release / October 8, 2018 PDF
Publication of Inside Information according to Article 17 MAR / October 3, 2018 PDF

 

For further information, please don’t hesitate to contact us:

Epigenomics AG
Geneststr. 5
10829 Berlin

Contact:
Peter Vogt
VP Corporate Communication & Investor Relations
E-Mail: ir@epigenomics.com
Tel: +49 30 243 45 – 386